Fraxetin

Fraxetin

SCHEMBL43472

COc1cc2ccc(=O)oc2c(O)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 9/20 1.00
CA12 O43570 7/20 1.00
CA1 P00915 7/20 1.00
CA7 P43166 7/20 1.00
CA13 Q8N1Q1 7/20 1.00
KDM4E B2RXH2 7/20 1.00
MCL1 Q07820 6/20 1.00
HSD17B10 Q99714 6/20 1.00
ALDH1A1 P00352 5/20 1.00
HPGD P15428 5/20 1.00
CASP1 P29466 3/20 1.00
CASP7 P55210 3/20 1.00
MAPT P10636 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
CYP2C9 P11712 2/20 1.00
CYP2C19 P33261 2/20 1.00
ALOX15 P16050 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fraxetin SCHEMBL30010613 1.00 CA9 (1.00) CA9CA12CA1CA7CA13
SCHEMBL14296936 0.89 CA9 (0.79) CA9CA12CA1CA7CA13
SCHEMBL3190311 0.87 CA9 (1.00) CA9CA12CA1CA7CA13
SCHEMBL30098746 0.87 CA9 (0.78) CA9CA12CA1CA7CA13
SCHEMBL29396102 0.87 CA9 (1.00) CA9CA12CA1CA7CA13
SCHEMBL3924718 0.87 CA9 (0.78) CA9CA12CA1CA7CA13
SCHEMBL16015213 0.87 CA9 (0.77) CA9CA12CA1CA7CA13
Methoxymethane SCHEMBL2253445 0.86 CA9 (0.97) CA9CA12CA1CA7CA13
SCHEMBL14316132 0.83 CA9 (0.71) CA9CA12CA1CA7CA13
SCHEMBL14296929 0.83 KDM4E (0.71) CA9CA12CA1CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250302799-A1 PHARMACEUTICAL COMPOSITION CONTAINING FRAXETIN FOR PREVENTION OR TREATMENT OF ENDOMETRIOSIS Research & Business Foundation Sungkyunkwan University (KR) 2025-10-02 US claimed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP claimed
EP-4479540-A1 COUMARIN SYNTHESIS AND USES THEREOF BASF SE (DE) 2024-12-25 EP claimed
US-20240392220-A1 BRANDY REPLICAS AVA FOOD LABS, INC. 2024-11-28 US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
EP-4408967-A1 BRANDY REPLICAS AVA FOOD LABS, INC. (US) 2024-08-07 EP claimed
EP-4362756-A1 NUT BUTTER REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS Voyage Foods, Inc. (US) 2024-05-08 EP claimed
CN-117159536-A Application of compound Fraxetin in preparation of medicines for preventing and treating pulmonary fibrosis 江南大学 2023-12-05 CN claimed
WO-2023156270-A1 COUMARIN SYNTHESIS AND USES THEREOF BASF SE (DE) 2023-08-24 WO claimed
WO-2023055801-A1 BRANDY REPLICAS AVA FOOD LABS, INC. (US) 2023-04-06 WO claimed
US-20040091589-A1 Prevention of synthetic color fading in beverages using botanically derived color stabilizers PEPSICO, INC. 2004-05-13 US claimed
JP-2003532634-A 2003-11-05 JP claimed
US-6576660-B1 Treating prostate cancer, breast cancer, obesity, skin disorders and baldness ARCH DEVELOPMENT CORPORATION 2003-06-10 US claimed
US-20020197370-A1 Deterioration preventive agent for milk-containing foods TAKASAGO INTERNATIONAL CORPORATION 2002-12-26 US claimed
US-6475544-B1 Anti-deterioration agent for food flavors, method for preventing deterioration of food flavors, and foods containing anti-deterioration agent for food flavors TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-11-05 US claimed
EP-1244435-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES Proteotech Inc. (US) 2002-10-02 EP claimed
EP-1240833-A2 Agent for prevention of deterioration of milk-containing foods Takasago International Corporation (JP) 2002-09-18 EP claimed
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTAMED, INC. 2001-11-29 US claimed
WO-2001049281-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES PROTEOTECH, INC. (US) 2001-07-12 WO claimed
US-5663029-A DEVELOPMENT OF LATENT IMAGE, TRANSFERRING TO FORM RECORDING SHEETS, COATING A SUBSTRATE USING POLYMERS XEROX CORPORATION (US) 1997-09-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302799-A1 PHARMACEUTICAL COMPOSITION CONTAINING FRAXETIN FOR PREVENTION OR TREATMENT OF ENDOMETRIOSIS SFXN1, NR5A1, LPXN CA9 1223/4885CA12 1057/4885CA1 2559/4885
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases SNCA, PARK7, HTT CA9 4753/4885CA12 4845/4885CA1 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.